Melanocytic Lesions of the Nail Unit

This article will first describe the histology of the nail unit, followed by a brief summary of clinical and histopathological features as well as differential diagnosis of melanocytic lesions of the nail unit.Dermatopathology 2018;5:98 –107
Source: Dermatopathology - Category: Pathology Source Type: research

Related Links:

CONCLUSION: Accurate assessment of the regional lymph node status by SNB is becoming even more important in the era of novel effective adjuvant therapies for microscopic nodal disease. Whether complete lymph node dissection is performed in patients with a positive SN needs to be assessed individually. In the case of "active nodal surveillance" instead of surgery, long-term close follow-up in specialized centers, including ultrasonographic controls, is required. PMID: 31605168 [PubMed - as supplied by publisher]
Source: Der Hautarzt: Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete - Category: Dermatology Tags: Hautarzt Source Type: research
CONCLUSIONS: STAT3-induced upregulation of SNHG17 contributed to the progression of melanoma by promoting the PI3K-AKT signaling. PMID: 31599425 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Authors: deShazo R, Soltani-Arabshahi R, Krishnasamy S, Langley RG, Kalia S, Ståhle M, Langholff W, Goyal K, Fakharzadeh S, Galindo C, Srivastava B, Krueger G Abstract To the Editor: Patients with psoriasis are at increased risk of developing non melanoma skin cancer (NMSC), including squamous cell carcinoma (SCC) and basal cell carcinoma (BCC).1,2 The risk is especially elevated among those who previously received systemic treatment or phototherapy.2 Systemic treatments, including biologic therapies and methotrexate (MTX), are effective in managing immune-mediated diseases; however, they may increase suscept...
Source: Journal of Drugs in Dermatology - Category: Dermatology Tags: J Drugs Dermatol Source Type: research
Getting a reliable diagnosis of melanoma can be a significant challenge for pathologists. The diagnosis relies on a pathologist ’s visual assessment of biopsy material on microscopic slides, which can often be subjective. Now, UCLA researchers have found that obtaining a second opinion from pathologists who are board certified or have fellowship training in dermatopathology can help improve the accuracy and reliability of diagnosing melanoma, one of the deadliest and most aggressive forms of skin cancer.“A diagnosis is the building block on which all other medical treatment is based,” said Dr. Joann ...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
Pancreatic cancer is a rare cancer that carries a poor 5 year survival rate of approximately 5% [1]. Approximately 5% to 10% of individuals with pancreatic cancer report having a closely related family member also being diagnosed with pancreatic cancer [2]. Several known genetic syndromes, such as hereditary breast-ovarian cancer syndrome (HBOC) [3], Lynch syndrome [4], familial adenomatous polyposis [5], familial atypical multiple mole melanoma syndrome [6], hereditary pancreatitis [7], Peutz-Jeghers syndrome [8], and Li-Fraumeni syndrome [9] are associated with increased risk of pancreatic cancer.
Source: Cancer Genetics and Cytogenetics - Category: Genetics & Stem Cells Authors: Source Type: research
Abstract In non-pigmented skin tumors the diagnosis is mainly based on the evaluation of the vascular morphology and vessels´ distribution dermoscopically [1-4]. However, up to date, no study formally correlated the prevailing vascular morphology with the thickness of melanoma according to Breslow and amount of pigmentation. PMID: 31605621 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Family Medicine, Oncology, News, Source Type: news
Conditions:   Melanoma;   Non-melanoma Skin Cancer Intervention:   Device: Deep Ensemble for the Recognition of Malignancy (DERM) Sponsors:   Skin Analytics Limited;   Innovate UK Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Malignant Melanoma Interventions:   Genetic: delolimogene mupadenorepvec;   Biological: atezolizumab Sponsors:   Lokon Pharma AB;   Precision Oncology LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Melanoma;   Non-melanoma Skin Cancer Intervention:   Device: Deep Ensemble for the Recognition of Malignancy (DERM) Sponsors:   Skin Analytics Limited;   Innovate UK Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Dermatology | Melanoma | Pathology | Skin Cancer